Cite
HARVARD Citation
Heck, M. et al. (2017). Chromogranin A and neurone‐specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration‐resistant prostate cancer undergoing abiraterone therapy. BJU international. pp. 30-37. [Online].